Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Naftali Kaminski

Pulmonary Disease New Haven, CT Medical Doctor

NPI 1376918870 CMS profile 1378548

20 York St, New Haven, CT 06510

Open in the dashboard

General payments

$179,905

61 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$832,815 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Naftali Kaminski of New Haven, CT is reported in the CMS Open Payments database as having received $179,905 across 61 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $832,815 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $595 1
2024 General $525 1
2023 General $28,349 26
2022 General $11,108 3
2021 General $111,689 7
2020 General $12,790 4
2019 General $14,850 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Naftali Kaminski
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Naftali Kaminski were reported at $595. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Naftali Kaminski Pulmonary Disease median Middle half National median
2019 $14,850 $377 $109–$1,340 $163
2020 $12,790 $230 $56–$907 $114
2021 $111,689 $269 $68–$1,072 $132
2022 $11,108 $390 $100–$1,457 $149
2023 $28,349 $419 $114–$1,659 $160
2024 $525 $476 $123–$1,818 $164
2025 $595 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $144,549 29 payments
  2. Merck Sharp & Dohme Corporation $18,710 24 payments
  3. AstraZeneca UK Limited $8,850 4 payments
  4. GlaxoSmithKline, LLC. $4,550 1 payment
  5. AstraZeneca AB $2,250 1 payment
  6. CSL Behring $940 1 payment
  7. Celgene Corporation $56 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $174,968 22 payments
  2. Travel and Lodging $2,324 13 payments
  3. Food and Beverage $1,673 25 payments
  4. Honoraria $940 1 payment
Products named General payments · program years 2019–2025
  1. OFEV $5,444 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record